Orthopedic Splints and Casts Market

Because 21 CFR 888.5940 classes cast components as Class I devices exempt from premarket notification, the fight in orthopedic splints and casts is won on handling, weight and price rather than on clearances. The Orthopedic Splints and Casts market covers the casting tape, plaster bandages, prefabricated and thermoplastic splints, undercast padding and stockinette that hold a fractured or sprained limb still, sold to hospitals, clinics and urgent care. Douglas Insights counts 145.5 million cast and splint applications in 2025 at an average USD 19.47 each, which gives USD 2.83 billion. Our model takes that to USD 4.33 billion by 2035, a revenue compound annual growth rate (CAGR) of 4.34%, from 3.1% volume growth and 1.2% price growth. In Europe the clock was reset when Regulation (EU) 2023/607, adopted on 15 March 2023, entered into force on 20 March 2023 and extended the Medical Device Regulation (MDR) transition for legacy devices. The study belongs to our orthopaedic devices coverage and follows the Douglas Insights research methodology.

Which companies supply orthopedic splints and casts, and how far ahead is Essity’s Delta-Cast?

Douglas Insights estimates Essity holds about 21.7% of 2025 orthopedic splint and cast revenue, or USD 614.7 million, through Delta-Cast and its wider fracture management range. The top three suppliers, adding Solventum and Enovis, hold about 39.8%, a basis built from company product ranges and disclosed segment sales.

Essity calls itself the global market leader in casting, sells its fracture management range in about 150 countries and covers every layer of a cast: Delta-Cast and Delta-Lite synthetic tape, Gypsona plaster, Dynacast splints, Delta-Dry padding and Delta Thermo thermoplastics. Its reach into liners came on 21 December 2021, when Essity bought AquaCast Liner, a Newark, Delaware maker of waterproof cast liners founded in 2012, at a price it called not material.

Solventum sells 3M Scotchcast Plus casting tape, which allows weight bearing within 20 minutes and comes in 13 colours; Douglas Insights puts its cast and splint share near 9.8%, or USD 277.6 million. Enovis, owner of the Aircast brand, sits close behind at an estimated 8.3%, or USD 235.1 million, once walkers and bracing outside our scope are stripped out.

Enovis disclosed on 6 August 2026 that US Bracing and Support sales reached USD 127.6 million in the second quarter of 2026, up 5.6%, inside a Prevention and Recovery segment of USD 288.2 million that grew 3.5% organically. Ottobock, founded in 1919 with about 9,300 employees and EUR 1.43 billion of revenue in its last full year, listed on the Frankfurt Stock Exchange on 9 October 2025 at an opening price of EUR 72.00, bringing fresh capital to its orthotics arm.

Orfit Industries of Wijnegem, Belgium, builds its position on low-temperature thermoplastic sheets for physical rehabilitation and orthotics, the raw material therapists mould into custom splints. Embla Medical reported that its Bracing and Supports sales fell 1% organically in 2025 while group sales grew 6%, a reminder that soft goods trail prosthetics. Readers following fixation hardware should see our Orthopedic Trauma Implants Market.

Which casting and splinting product makes the money: fiberglass tape, plaster or thermoplastic sheets?

Fiberglass and synthetic casting tape leads orthopedic splints and casts with 34.6% of 2025 value, or USD 980.2 million, because a synthetic cast weighs less and sets faster than plaster. Thermoplastic splinting sheets are the fastest-growing segment at 6.3% a year, reaching USD 438.4 million by 2035.

Fiberglass and synthetic casting tape holds USD 980.2 million because each cast uses two to four rolls and the tape commands a premium over plaster; it grows 5.2% a year to USD 1.63 billion. Prefabricated splints carry USD 790.4 million, a 27.9% share, since a ready-made wrist or ankle splint fits a sprain in minutes without a technician.

Undercast padding and stockinette account for USD 433.4 million, or 15.3%, riding on every cast applied, and waterproof liners such as AquaCast lift their value per cast. Plaster of Paris bandages and slabs hold USD 390.9 million but grow only 1.1% a year, as fracture clinics in richer markets switch to synthetics and keep plaster for the first swollen days.

Thermoplastic splinting sheets are the smallest segment at USD 238.0 million, and the fastest at 6.3% a year. Therapists mould them at low temperature into custom hand and thumb splints, and the shift of hand therapy into outpatient clinics adds patients every year.

Why are fragility fractures in older adults lifting cast and splint volumes?

Orthopedic splint and cast applications grow 3.1% a year to 2035, from three forces. Ageing and fragility fractures add 1.4 points, rising trauma care in Asia Pacific adds 0.9 points and the outpatient shift to prefabricated splints for sprains adds 0.8 points, together the full volume leg.

Ageing and fragility fractures add 1.4 points

The fracture pool is large and rising. The World Health Organization (WHO) counts 178 million new fractures worldwide in 2019, 33.4% more than in 1990, and 455 million people living with acute or long-term fracture symptoms, up 70.1%. Fractures caused 25.8 million years lived with disability that year, a 65.3% rise. WHO notes that wrist, hip, spine and upper arm fractures dominate among older people, especially older women, and the wrist is the classic cast fracture. Douglas Insights converts that trend into 1.4 points of yearly growth in orthopedic splint and cast applications, the largest single driver, because every distal forearm fracture in an older patient means a back slab, a full cast and often a removable splint afterwards.

Trauma care in Asia Pacific adds 0.9 points

Hospital capacity is the second force. Road traffic and fall injuries in China, India and Southeast Asia are increasingly treated in hospitals with casting rooms rather than by traditional bone setters, and every patient moved into formal care becomes a buyer of casting tape or plaster. Douglas Insights places this effect at 0.9 points, which is why Asia Pacific orthopedic splint and cast revenue grows 6.4% a year in our model against 3.6% in North America. Synthetic tape gains most here, since new casting rooms tend to stock fiberglass from day one rather than plaster, and each of those rooms buys tape, padding and stockinette on a single contract with one of the six suppliers named above.

Prefabricated splints for sprains add 0.8 points

The third force is the outpatient shift. Urgent care centres and physiotherapists now treat ankle sprains, scaphoid suspicions and stable wrist fractures with a prefabricated splint that a nurse fits in a few minutes. Enovis reported US Bracing and Support sales up 5.6% in the second quarter of 2026, the clearest public sign of that pull. Douglas Insights adds 0.8 points of application growth for it. The three contributions, 1.4, 0.9 and 0.8 points, add to the 3.1% volume leg, while price adds 1.2% a year as synthetics replace plaster.

What stands in the way of orthopedic cast and splint volumes outside the fracture clinic?

Three restraints remove about 1.2 points from orthopedic splint and cast volume growth. Surgical plating of wrist fractures takes 0.5 points, tight budgets in low-income hospitals 0.4 points and soft bracing weakness 0.3 points; without them, applications would grow near 4.3% a year.

Surgical fixation removes 0.5 points. More unstable distal radius fractures are now fixed with a volar plate, which shortens or replaces the cast period; each plated wrist means one fewer full cast and often only a short splint. Our sister study, the Orthopedic Trauma Implants Market, tracks that hardware.

Budget limits remove 0.4 points. In many low-income hospitals one plaster roll still costs a fraction of a synthetic roll, and WHO data show the fracture burden growing fastest where health budgets are thinnest. Orthopedic splint and cast use rises with fractures there, but spend per application stays near the plaster floor of about USD 4.

Soft bracing weakness removes 0.3 points. Embla Medical’s Bracing and Supports sales fell 1% organically in 2025 even as its group grew 6%, and Enovis’s Prevention and Recovery segment fell 0.8% on a reported basis in its latest quarter after divestitures. Prefabricated splints share that channel, so slow reimbursement for off-the-shelf orthoses drags on volume.

Where do orthopedic splint and cast sales grow fastest: Asia Pacific or North America?

North America leads orthopedic splint and cast spending with USD 985.8 million in 2025, or 34.8%, because synthetic casts and prefabricated splints dominate its emergency departments. Asia Pacific grows fastest at 6.4% a year, from USD 753.6 million to USD 1.40 billion by 2035, as formal trauma care spreads.

North America reaches USD 1.40 billion by 2035 at 3.6% a year. Europe holds USD 787.5 million and grows 2.9% a year to USD 1.05 billion, the slowest pace, because plaster still holds a large share in public fracture clinics and MDR compliance adds overhead. Asia Pacific, at 26.6% of 2025 value, nearly catches North America by 2035.

Latin America is the wildcard at USD 178.5 million, growing 5.1% a year to USD 293.5 million if public hospitals in Brazil and Mexico move from plaster to synthetic tape. Middle East and Africa is the smallest region at USD 127.5 million and grows 3.75% a year to USD 184.2 million, held near plaster prices by public tenders.

How much does a fiberglass cast or a thermoplastic splint earn its maker per application?

An orthopedic splint or cast application earned its makers USD 19.47 on average in 2025 across tape, padding and splint, and Douglas Insights expects USD 21.94 by 2035. Realised bands, all our estimates, run from about USD 4 for a plaster application to USD 70 for a custom thermoplastic splint.

The average rises 1.2% a year because the mix moves to synthetics, not because list prices climb. A hospital that swaps a USD 6 plaster cast for a USD 24 fiberglass cast quadruples its materials spend on that patient while saving on cast changes. Waterproof liners and coloured tapes push the top of the synthetic band; Scotchcast Plus alone comes in 13 colours. Group purchasing contracts in North America and public tenders in Europe cap the top of each band, and prices for the same roll can differ by a third between a tendered hospital and a small clinic.

Which care settings apply most casts: hospitals, fracture clinics or urgent care?

Douglas Insights estimates Hospitals apply 52.6% of 2025 orthopedic splint and cast value, USD 1.49 billion, through emergency departments and plaster rooms. Orthopedic and fracture clinics take 31.8%, or USD 900.9 million, and Urgent care and physiotherapy settings 15.6%, or USD 441.9 million.

Hospitals lead because the first cast follows the first X-ray, usually in an emergency department. Orthopedic and fracture clinics apply the definitive cast at the follow-up visit and replace it when swelling falls, so one fracture often uses two casts. Urgent care and physiotherapy settings grow fastest among end users, since prefabricated splints and thermoplastic sheets need no plaster room. A cast that is waterproof also links casting to skin care, covered in our Wound Care Market.

Is plaster of Paris disappearing from fracture clinics?

No: plaster of Paris bandages and slabs still earn USD 390.9 million in 2025 and USD 436.1 million by 2035, growing 1.1% a year. Their share of orthopedic splint and cast value falls from 13.8% to about 10.1%, because plaster stays the cheapest way to make a back slab over a swollen limb.

Essity still sells Gypsona and Biplatrix plaster alongside its synthetics, which shows that the leading supplier expects plaster to survive. Plaster sets slowly, moulds closely and can be split easily, so many clinicians keep it for the first days after injury and for children’s fractures that need close moulding. The synthetic switch happens at the second cast. Douglas Insights expects the synthetic-to-plaster value ratio to rise from 3.12 in 2025 to 4.74 in 2035, a measure tracked in the index below.

Which rules govern cast components and casting tape, from FDA Class I to the EU MDR?

Orthopedic splint and cast components sold in the US are Class I devices: 21 CFR 888.5940 covers cast heels, toe caps, cast supports and walking irons and exempts them from premarket notification. In the European Union (EU), Regulation (EU) 2023/607 entered into force on 20 March 2023 to extend MDR transition periods.

The US rule also exempts these devices from most current good manufacturing practice requirements, keeping only records and complaint files. The consequence is a low entry barrier: a new casting or splint supplier needs a listing and a quality file, not a clearance, so private-label tape competes directly with branded tape. That cap on pricing power is part of why the price leg is only 1.2% a year.

In Europe, Regulation (EU) 2023/607 was adopted on 15 March 2023 and amends Regulation (EU) 2017/745, the MDR. Suppliers of legacy orthopedic splint and cast products gained more time to move their certificates, but each must still build MDR technical files, which favours suppliers with large portfolios such as Essity. Douglas Insights treats the compliance effort as part of the slower European growth of 2.9% a year.

What if hip fractures rise faster: orthopedic splints and casts in 2035 under three cases?

Orthopedic splint and cast revenue reaches USD 4.33 billion in 2035 in the base case. A slower case lands at USD 3.63 billion, a 2.51% CAGR, and a faster case at USD 5.11 billion, a 6.08% CAGR, a gap of USD 1.48 billion between the outer cases.

The slower case runs volume at 1.9% and price at 0.6%: volar plating spreads further, plaster keeps its share in Asia Pacific and bracing reimbursement tightens, as Embla’s 1% organic decline in Bracing and Supports already hints. The faster case runs volume at 4.2% and price at 1.8%: fragility fractures outpace the WHO trend, synthetic tape becomes standard in new Asian casting rooms and the MDR file burden pushes small plaster makers out after the extension under Regulation (EU) 2023/607 runs out.

One extra point of yearly application growth adds about USD 439.0 million to the 2035 orthopedic splint and cast total; one point less takes away about USD 402.2 million. Outside forecasts we read span 4.2% to 10.0% a year, and our 4.34% sits at the low end because we exclude walkers and soft bracing; the 10.0% figure counts splints alone.

Douglas Exclusive: the Synthetic Immobilisation Shift Index

The Synthetic Immobilisation Shift Index is a Douglas Insights model built from 10 inputs: the 2025 value and growth rate of each of our 5 orthopedic splint and cast segments. It divides synthetic value, fiberglass tape plus thermoplastic sheets, by plaster value, and sets 2025 at 100.

The index counts how fast orthopedic splint and cast buyers trade plaster for synthetics, a better signal of supplier margins than total volume. Its finding is that the index reaches 152.0 by 2035, so each plaster dollar is matched by USD 4.74 of synthetic material, yet synthetics still stay under half of the market at 47.6%. Padding and prefabricated splints, not plaster, hold the rest.

The index is a model, not an official register, and it moves with our segment growth rates. A 1-point faster plaster decline would push the 2035 reading to about 168, which is why we will re-check it against supplier disclosures at the next review.

Methodology: how do 178 million fractures become 145.5 million cast and splint applications?

WHO’s 178 million fractures in 2019, grown at the 1.00% yearly rate implied by the 33.4% rise since 1990, give about 188.9 million fractures in 2025. Douglas Insights applies 0.77 cast and splint applications per fracture, sprain splints included, for 145.5 million applications.

Multiplied by USD 19.47, that is USD 2.83 billion. The 2026 value is USD 2.96 billion. Applications grow 3.1% a year to 197.4 million in 2035, at USD 21.94 each, giving USD 4.33 billion. The model covers 5 regions, 5 product segments and 3 end-user groups, and draws on 24 sourced data points from 8 primary documents.

Regional values sum to the global total within USD 0.1 million in 2025 and 2035; segment values sum exactly in 2025 and within 0.22% in 2035. Three cross-checks were run. The one outside 2025 estimate we read for casting and splinting products, USD 2.8 billion, sits 1.2% below ours. Our 4.34% CAGR falls 2.76 points under the 7.10% midpoint of the published range of 4.2% to 10.0%, consistent with our narrower scope. Essity’s estimated USD 614.7 million fits a supplier that sells in about 150 countries.

Sources

1. eCFR, US Government 21 CFR 888.5940 Cast component (2026)
2. EUR-Lex Regulation (EU) 2023/607 amending Regulations (EU) 2017/745 and 2017/746 (2023)
3. World Health Organization Fragility fractures fact sheet (2024)
4. SEC EDGAR Enovis second quarter 2026 results, Form 8-K (2026)
5. Essity Essity acquisitions, investments and divestments 2021 (2021)
6. Deutsche Boerse Ottobock new in the Prime Standard of the Frankfurt Stock Exchange (2025)
7. Essity Fracture management product brochure (2025)
8. Solventum 3M Scotchcast Plus Casting Tape (2026)